Novo Nordisk has multiple weight-loss drugs in various stages of development and approval, according to its R&D pipeline. These include, among others, monlunabant (phase 2); oral and subcutaneous ...
Contineum Therapeutics, Inc. (CTNM) has been able to do well to advance the use of an LPA1R antagonist for the treatment of neuroinflammatory disorders in a phase 1 healthy volunteer study. Why ...
A sweeping review of dozens of clinical trials suggests that today’s most widely used GLP-1 receptor agonist drugs produce broadly consistent weight-loss results across age, race, ethnicity, and ...
ST316 interfered with β-catenin immune-exclusion allowing for stronger cytotoxic T-cell activity. The Food and Drug Administration (FDA) has granted Orphan Drug designation to ST316 for the treatment ...
Vimgreen Pharmaceuticals, a leading innovator in adenosine signaling modulation, today announced the approval of its Investigational New Drug (IND) application for VG081821 in non‑alcoholic ...
The "LAG-3 Antagonist – Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com’s offering. This "LAG-3 Antagonist – Pipeline Insight, 2021," report provides comprehensive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results